John Rhodes, MD
Dr. John Rhodes is a pediatric and adult congenital invasive cardiologist. He received his medical degree from The Brody School of Medicine in Greenville, North Carolina, completed his residency in pediatrics at the Medical University of South Carolina, and a fellowship in cardiology at the Mount Sinai Medical Center in New York City. He also pursued additional training in pediatric and adult congenital interventional cardiac catheterization at The Cleveland Clinic Foundation in Cleveland, Ohio.
Dr. Rhodes has recently returned the Medical University of South Carolina in Charleston as the operations director for the Congenital Heart Center and as an interventional specialist for children and adults with congenital heart disease. Prior to joining the Congenital Heart Center, Dr. Rhodes worked from 2003 to 2013 at Duke University Medical Center in Durham, North Carolina as chief of the Duke Children’s Heart Center, director of the Pediatric & Adult Congenital Interventional Cardiac Catheterization Laboratory, and co-director of the Adult Congenital Heart Program. More recently, Dr. Rhodes worked from 2013 to 2017 at Nicklaus Children’s Health System in Miami, Florida as the director of cardiology, director of adult congenital, and director of the Interventional Cardiac Catheterization Laboratory.
Dr. Rhodes’ clinical interests involve diagnostic and interventional catheterization procedures for adults and children with complex congenital heart disease. He has helped pioneer several techniques, including transcatheter atrial septal defect (ASD) closure with the CARDIOFORM Gore Helex™ Septal Occluder device, intracardiac echocardiographic imaging to guide catheter interventions, cutting balloon angioplasty of stenotic branch pulmonary arteries, and pulmonary vein stent angioplasty for pulmonary vein stenosis following radiofrequency ablation of atrial fibrillation. He also served as the national principal investigator for the REDUCE trial for the management of patients for stroke-related patent foramen ovale device closure and is an investigator for trials including the Edwards Lifesciences transcatheter SAPIEN pulmonary stent valve, the MELODY pulmonary stent valve post approval study, the new CARDIOFORM Gore Atrial Septal Defect (ASD) Occluder device, and bare metal as well as covered stent angioplasty for coarctation of the aorta. Other clinical expertise includes congenital heart syndromes such as Marfan syndrome, Down syndrome, and Williams syndrome as well as hereditary telangiectasia (HHT) and associated pulmonary arteriovenous malformations.